<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00913484</url>
  </required_header>
  <id_info>
    <org_study_id>1R01DA012979</org_study_id>
    <secondary_id>1R01DA012979</secondary_id>
    <nct_id>NCT00913484</nct_id>
  </id_info>
  <brief_title>Disulfiram for Cocaine Abuse in Buprenorphine Treatment</brief_title>
  <official_title>Disulfiram for Cocaine Abuse in Buprenorphine Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <brief_summary>
    <textblock>
      The investigators are proposing a placebo-controlled clinical trial to evaluate the efficacy&#xD;
      and potential mechanisms of action of disulfiram (versus placebo) for treating cocaine abuse&#xD;
      in subjects with concurrent opiate dependence and cocaine abuse or dependence maintained on&#xD;
      buprenorphine/naloxone combination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Specific Aims and hypotheses for the proposed study are as follows:&#xD;
&#xD;
        1. To compare the efficacy of disulfiram versus placebo for the treatment of buprenorphine&#xD;
           maintained patients with concurrent opioid and cocaine dependence. Study hypothesis 1 is&#xD;
           that disulfiram is superior to placebo.&#xD;
&#xD;
        2. To evaluate whether dopamine-B-hydroxylase (DBH) genotypes associated with high,&#xD;
           intermediate or low enzyme activity predict responses to disulfiram treatment of cocaine&#xD;
           use in buprenorphine treated subjects. Study hypothesis 2 is that disulfiram efficacy is&#xD;
           higher in subjects with low DBH compared to subjects with high DBH.&#xD;
&#xD;
        3. To explore whether baseline measures of alcohol use predict response to disulfiram.&#xD;
           Study Hypothesis 3 is that the effects of disulfiram on cocaine use are independent of&#xD;
           the severity of baseline alcohol use.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2000</start_date>
  <completion_date type="Actual">February 2004</completion_date>
  <primary_completion_date type="Actual">February 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cocaine abstinence</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opioid abstinence</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">177</enrollment>
  <condition>Cocaine Dependence</condition>
  <condition>Opioid Dependency</condition>
  <arm_group>
    <arm_group_label>Disulfiram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Disulfiram 250 mg per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Disulfiram</intervention_name>
    <description>Disulfiram 250 mg per day</description>
    <arm_group_label>Disulfiram</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  English speaking adults ages 18 - 45.&#xD;
&#xD;
          -  Meeting FDA criteria for agonist maintenance treatment and DSM-IV criteria for opioid&#xD;
             dependence and cocaine dependence or abuse as assessed by SCID interview and&#xD;
             documented by opioid positive and cocaine positive urine toxicology testing.&#xD;
&#xD;
          -  Women of childbearing age will be included provided they agree to adequate&#xD;
             contraception and to monthly pregnancy testing during the course of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current physiologic dependence on benzodiazepines or alcohol, unless first detoxified.&#xD;
             Subjects who use/abuse alcohol will be included but will be cautioned about alcohol&#xD;
             use during the study because of the possibility of an alcohol-disulfiram reaction.&#xD;
&#xD;
          -  Use of the antibiotic agents metronidazole or clotrimazole, which have disulfiram-like&#xD;
             effects in combination with alcohol.&#xD;
&#xD;
          -  Presence of significant cardiovascular, renal, hepatic or neurologic illness. Subjects&#xD;
             with markedly abnormal liver function tests (i.e., AST of ALT &gt; 3X normal) will also&#xD;
             be excluded.&#xD;
&#xD;
          -  Presence of any of the following cardiovascular risk factors:&#xD;
&#xD;
               -  age &gt; 45 years&#xD;
&#xD;
               -  history of cocaine-related chest pain&#xD;
&#xD;
               -  systolic blood pressure &gt; 140 or diastolic blood pressure &gt; 90&#xD;
&#xD;
               -  evidence of ischemia or past myocardial infarction on EKG&#xD;
&#xD;
               -  significant family history of risk (first degree relative with myocardial&#xD;
                  infarction prior to age 60)&#xD;
&#xD;
               -  elevated cholesterol (&gt; 300 mg/dl), elevated LDL (&gt; 170 mg/dl) or low HDL (&lt; 20&#xD;
                  mg/dl)&#xD;
&#xD;
          -  Maintenance on methadone at doses greater than 30mg daily. Admittance to the study&#xD;
             will only be offered to individuals who have been maintained on 30 mg of methadone or&#xD;
             less daily for seven days prior to entering the study.&#xD;
&#xD;
          -  Current suicide or homicide risk or current psychotic disorder.&#xD;
&#xD;
          -  Inability to read or understand the symptom checklists.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard S. Schottenfeld, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The APT Foundation MRU</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 3, 2009</study_first_submitted>
  <study_first_submitted_qc>June 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2009</study_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Disulfiram</keyword>
  <keyword>Buprenorphine</keyword>
  <keyword>Cocaine dependence</keyword>
  <keyword>Opioid dependence</keyword>
  <keyword>Dopamine-Beta-Hydroxylase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disulfiram</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

